Drug Profile


Alternative Names: 1-methylnicotinamide cation; 1-MNA; MNA; NMN; TRIA 662; TRIA-662; Trigonellinamide

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator Technical University of Lodz
  • Developer Cortria Corporation
  • Class Amides; Antihyperlipidaemics; Nicotinic-acids; Pyridinium compounds; Small molecules; Vitamins
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Hyperlipidaemia

Most Recent Events

  • 01 Oct 2015 Cortria Corporation completes a phase II trial for Hyperlipidaemia in Canada (NCT02008084)
  • 19 Jun 2015 Phase-II/III development for Hyperlipidaemia is ongoing in Canada
  • 06 Dec 2013 Cortria Corporation initiates enrolment in a phase II trial for Hyperlipidaemia in Canada (NCT02008084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top